Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories Ltd. Q1 FY2025 earnings call
July 27, 2024 · fiscal period ended 2024-06
EPS · actual vs est
Revenue · actual vs est
Summary
Generated 2024-07-27
Management highlights
Financial Performance
- Consolidated revenue grew 14% YOY and 8% QOQ, driven by generic business in US and Sanofi vaccine portfolio in India.
- Gross margin 60.4%, up 170bps YOY. SG&A up 28% YOY due to investments in new business, etc. R&D up 24% YOY.
Business Highlights
- Acquired Nicotinell for consumer health care, strategic collaborations with Takeda, Novartis, etc.
- Inaugurated Aurigene biologics facility in Hyderabad.
- Recognized for ESG efforts, featured in global sustainable companies list.
Leadership Change
- Parag Agarwal retiring, MV Narasimham to take over as CFO from August 1, 2024.
Segment performance
Consolidated revenue for Q1 FY '25 stood at INR 7,673 crores (USD 921 million), growing 14% YOY and 8% QOQ. Global Generics: Revenue $463 million, Y/Y growth 19%, Q/Q growth 18%, volume-led with new launches. European Generics: Revenue $59 million, Y/Y growth 4%, Q/Q growth 1%, base volume and new launches offset price erosion. Emerging Market Generics: INR 1,188 crores, Y/Y growth 3%, Q/Q decline 2%, market share expansion and new products offset forex. India Business: Revenue INR 1,325 crores, Y/Y growth 15%, driven by Sanofi vaccine portfolio and new launches. PSAI: Revenue $92 million, Y/Y growth 12%, Q/Q decline 7%, volume improvement and new launches.
Guidance
SG&A
- Expected to be 27.5%-28% of sales for full fiscal.
R&D
- Investment expected 8.5%-9% of sales for full fiscal.
Cash Flow
- Free cash flow generated INR 227 crores, net surplus cash INR 6,731 crores.
India Business
- Base growth to be double digits for the year and future quarters.
Risks
- Freight rate increases and one-off expenses contributing to SG&A increase.
- Regulatory issues from U.S. FDA inspections with Form 483 observations.
- Fluctuations in factoring affecting cash flow generation.
Q&A highlights
Q: Cash flow from operations moderated?
A: Fluctuation in factoring, expected to pick up going forward.
Q: SG&A step jump?
A: Investments in new business initiatives, some one-offs like freight rate increase.
Q: U.S. launch momentum?
A: On track, growth to continue.
Q: India business growth?
A: Base growth to be double digits for the year and future quarters.
Q: Biologics spend and timelines?
A: Biosimilars 20% of R&D, 10% of CapEx, sales from 2027, abatacept filing end 2025, launch end 2026.
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | $0.20 | $0.22 | -9.1% | $0.21 |
| Revenue | $920.7M | $921.8M | -0.1% | $821.2M |
Transcript
July 27, 2024Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.